Episomal Suicide Construct for Stem Cell Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for eliminating residual pluripotent stem cells from differentiated cell populations face challenges due to the risk of tumor formation, with genetic modifications using suicide genes raising concerns about insertional mutagenesis and unpredictable expression.
Innovation Solution
A composition comprising an episomal maintenance element and a target gene, where the episomal maintenance element is regulated by a constitutive promoter and the target gene by a non-constitutive promoter, specifically an undifferentiated stem cell-specific promoter, to ensure long-term episomal maintenance and selective expression of the target gene in a subset of cells, such as thymidine kinase, inducing susceptibility to cell death upon ganciclovir administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If genetic modification using suicide genes is used to eliminate residual pluripotent stem cells, then tumor formation risk is reduced, but insertional mutagenesis and unpredictable expression occur
Solution Approach 1:
The patent divides the genetic modification approach into two distinct components: (1) an episomal maintenance element that ensures stable inheritance without integration, and (2) a suicide gene expressed under a non-constitutive promoter for selective cell elimination. This segmentation avoids insertional mutagenesis by preventing genome integration while maintaining the therapeutic function.
Solution Approach 2:
The patent introduces an episomal vector as an intermediary carrier that temporarily delivers the suicide gene without integrating into the host genome. This episomal intermediate allows for controlled gene expression and cell selection while avoiding the harmful effects of permanent genomic integration.
2Stability of the object's composition
If transgenes are integrated into the genome by plasmid or lentiviral integration, then stable expression is achieved, but position effects and silencing occur making expression unreliable
Solution Approach 1:
The patent extracts the transgene expression system from the integrated genome context and places it on an episomal vector that maintains independence from host chromosomal position. This extraction eliminates position effects and silencing while maintaining stable inheritance through the episomal replication mechanism.
Solution Approach 2:
The patent changes the physical state of the transgene from integrated chromosomal DNA to extrachromosomal episomal DNA. This parameter change in localization and replication mechanism provides stable expression without the negative effects of genomic integration, including position effects and epigenetic silencing.
3Duration of action of stationary object
If constitutive promoter is used to drive episomal maintenance element, then long-term episomal maintenance is achieved in entire cell population, but target gene expression becomes unpredictable
Solution Approach 1:
The patent segments the promoter functions into two distinct elements: a constitutive promoter driving the episomal maintenance element for stable inheritance, and a non-constitutive promoter driving the target gene for controlled expression. This segmentation allows independent optimization of each function without interference.
Solution Approach 2:
The patent applies different promoter characteristics to different genetic elements: a constitutive promoter for the episomal maintenance element where continuous expression is needed, and a non-constitutive promoter for the target gene where regulated expression is required. This local differentiation of promoter properties enables both stable maintenance and controlled expression.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces or prevents tumor formation by selectively eliminating undifferentiated stem cells while maintaining the episomal construct in the entire cell population, ensuring long-term stability and safety in stem cell therapies.
Implementation Method 1
plasmid vectors containing the scaffold/matrix attached regions (S/MAR) of the human interferon-β gene can maintain their state as episomal DNA in cells of various species
Implementation Method 2
the expression of the episomal maintenance element is regulated by a constitutive promoter
Implementation Method 3
the expression of the target gene is regulated by a non-constitutive promoter... specifically an undifferentiated stem cell-specific promoter
Implementation Method 4
such as thymidine kinase, inducing susceptibility to cell death upon ganciclovir administration
Implementation Method 5
selectively eliminating undifferentiated stem cells while maintaining the episomal construct in the entire cell population
Data Source
AI summary
The invention includes compositions and methods for the selective expression of a target gene in a subset of cells. In certain embodiments, the present invention includes a construct comprising a first nucleic acid sequence comprising an episomal maintenance element and a second nucleic acid sequence comprising a target gene wherein the expression of the episomal maintenance element is regulated by a constitutive promoter and the expression of the target gene is regulated by a non-constitutive promoter. The construct is able to maintain episomal state, no matter whether the target gene is expressed in the cell.